166 related articles for article (PubMed ID: 3366493)
21. Evaluation of genetic toxicity of 6-diazo-5-oxo-l-norleucine (DON).
Kulkarni RM; Dakoulas EW; Miller KE; Terse PS
Toxicol Mech Methods; 2017 Sep; 27(7):518-527. PubMed ID: 28552037
[TBL] [Abstract][Full Text] [Related]
22. Influence of 6-diazo-5-oxo-L-norleucine (DON), a glutamine analogue, on cartilaginous differentiation in mouse limb buds in vitro.
Aydelotte MB; Kochhar DM
Differentiation; 1975 Oct; 4(2):73-80. PubMed ID: 1183764
[TBL] [Abstract][Full Text] [Related]
23. Isolation and characterization of a mutant Chinese hamster cell line resistant to the glutamine analog 6-diazo-5-oxo-L-norleucine.
Kaufman ER
Somat Cell Mol Genet; 1985 Jan; 11(1):1-10. PubMed ID: 3856328
[TBL] [Abstract][Full Text] [Related]
24. Effect of 6-diazo-5-oxo-L-norleucine (DON) on human carcinoid tumor cell aggregates.
Wu F; Bergström M; Stridsberg M; Orlefors H; Eriksson B; Oberg K; Watanabe Y; Långstrom B
Anticancer Res; 1997; 17(4A):2363-7. PubMed ID: 9252648
[TBL] [Abstract][Full Text] [Related]
25. Protective Effects of Glutamine Antagonist 6-Diazo-5-Oxo-l-Norleucine in Mice with Alphavirus Encephalomyelitis.
Manivannan S; Baxter VK; Schultz KL; Slusher BS; Griffin DE
J Virol; 2016 Oct; 90(20):9251-62. PubMed ID: 27489275
[TBL] [Abstract][Full Text] [Related]
26. Limb development in mouse embryos: protection against teratogenic effects of 6-diazo-5-ox-L-norleucine (DON) in vivo and in vitro.
Greene RM; Kochhar DM
J Embryol Exp Morphol; 1975 Apr; 33(2):355-70. PubMed ID: 1176851
[TBL] [Abstract][Full Text] [Related]
27. Poliovirus and vesicular stomatitis virus replication in the presence of 6-diazo-5-oxo-L-norleucine or 2-deoxy-D-glucose.
Goldstein G; Guskey LE
J Med Virol; 1984; 14(2):159-67. PubMed ID: 6208320
[TBL] [Abstract][Full Text] [Related]
28. Effects of diazo-oxo-norleucine on cell kinetics and odontoblast differentiation in cultured embryonic mouse molars.
Olive M; Ruch JV
Arch Oral Biol; 1982; 27(6):505-11. PubMed ID: 6956264
[TBL] [Abstract][Full Text] [Related]
29. A redox-responsive prodrug for tumor-targeted glutamine restriction.
Prange CJ; Sayed NYB; Feng B; Goepfert C; Trujillo DO; Hu X; Tang L
J Control Release; 2024 Apr; 368():251-264. PubMed ID: 38403173
[TBL] [Abstract][Full Text] [Related]
30. Model studies towards prodrugs of the glutamine antagonist 6-diazo-5-oxo-l-norleucine (DON) containing a diazo precursor.
Gao RD; Hin N; Prchalová E; Pal A; Lam J; Rais R; Slusher BS; Tsukamoto T
Bioorg Med Chem Lett; 2021 Oct; 50():128321. PubMed ID: 34400301
[TBL] [Abstract][Full Text] [Related]
31. Characterization of L-threonine and L-glutamine transport in murine P388 leukemia cells in vitro. Presence of an N-like amino acid transport system.
Lazarus P; Panasci LC
Biochim Biophys Acta; 1986 Apr; 856(3):488-95. PubMed ID: 3083865
[TBL] [Abstract][Full Text] [Related]
32. Effect of acivicin on glutamine transport by rat renal brush border membrane vesicles.
Sastrasinh S; Sastrasinh M
J Lab Clin Med; 1986 Oct; 108(4):301-8. PubMed ID: 2876045
[TBL] [Abstract][Full Text] [Related]
33. Novel Glutamine Antagonist JHU395 Suppresses MYC-Driven Medulloblastoma Growth and Induces Apoptosis.
Pham K; Maxwell MJ; Sweeney H; Alt J; Rais R; Eberhart CG; Slusher BS; Raabe EH
J Neuropathol Exp Neurol; 2021 Mar; 80(4):336-344. PubMed ID: 33712838
[TBL] [Abstract][Full Text] [Related]
34. Combination chemotherapy in vitro exploiting glutamine metabolism of human glioma and medulloblastoma.
Dranoff G; Elion GB; Friedman HS; Bigner DD
Cancer Res; 1985 Sep; 45(9):4082-6. PubMed ID: 4028000
[TBL] [Abstract][Full Text] [Related]
35. Inactivation of rat renal phosphate-dependent glutaminase with 6-diazo-5-oxo-L-norleucine. Evidence for interaction at the glutamine binding site.
Shapiro RA; Clark VM; Curthoys NP
J Biol Chem; 1979 Apr; 254(8):2835-8. PubMed ID: 429321
[TBL] [Abstract][Full Text] [Related]
36. Monocytoid differentiation of freshly isolated human myeloid leukemia cells and HL-60 cells induced by the glutamine antagonist acivicin.
Nichols KE; Chitneni SR; Moore JO; Weinberg JB
Blood; 1989 Oct; 74(5):1728-37. PubMed ID: 2790198
[TBL] [Abstract][Full Text] [Related]
37. The effects of 6-diazo-5-oxo-L-norleucine, a glutamine analogue, on the structure of the major cartilage proteoglycan synthesized by cultured chondrocytes.
Clark CC; Richards CF; Pacifici M; Iozzo RV
J Biol Chem; 1987 Jul; 262(21):10229-38. PubMed ID: 3112139
[TBL] [Abstract][Full Text] [Related]
38. Glutamine Antagonist JHU083 Normalizes Aberrant Glutamate Production and Cognitive Deficits in the EcoHIV Murine Model of HIV-Associated Neurocognitive Disorders.
Nedelcovych MT; Kim BH; Zhu X; Lovell LE; Manning AA; Kelschenbach J; Hadas E; Chao W; Prchalová E; Dash RP; Wu Y; Alt J; Thomas AG; Rais R; Kamiya A; Volsky DJ; Slusher BS
J Neuroimmune Pharmacol; 2019 Sep; 14(3):391-400. PubMed ID: 31209775
[TBL] [Abstract][Full Text] [Related]
39. Phase II evaluation of DON (6-diazo-5-oxo-L-norleucine) in patients with advanced colorectal carcinoma.
Lynch G; Kemeny N; Casper E
Am J Clin Oncol; 1982 Oct; 5(5):541-3. PubMed ID: 7180833
[TBL] [Abstract][Full Text] [Related]
40. Acivicin reduces tumor growth during total parenteral nutrition (TPN).
Chance WT; Cao L; Nelson JL; Foley-Nelson T; Fischer JE
Surgery; 1987 Aug; 102(2):386-94. PubMed ID: 3112985
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
